文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局限性前列腺癌的立体定向磁共振引导每日自适应放疗:急性和晚期患者报告毒性结局

Stereotactic Magnetic Resonance-Guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer: Acute and Late Patient-Reported Toxicity Outcomes.
PubMed 文献 · Adv Radiat Oncol · 2024-07-18

本研究纳入69例接受36.25 Gy/5次立体定向磁共振引导每日自适应放疗的局限性前列腺癌患者,中位随访27个月,采用12项患者报告结局版常见不良事件术语标准问卷评估肠道、泌尿和性功能毒性。随访期间无患者出现生化失败,肠道症状多数无变化,新发严重性功能障碍见于26%患者且持续至33个月以上。

要点

  • 69例患者接受36.25 Gy/5次SMART,中位随访27个月,随访期间无生化失败。
  • 肠道症状方面超过80%患者报告无变化,新发≥频繁或几乎持续腹泻见于9%。
  • 新发严重性功能障碍见于26%患者,且在33个月以上持续存在。

核心结论

  • 本研究是前列腺SMART后较大的患者报告结局研究之一,显示即使治疗后随访至2年,毒性水平可接受。

研究设计与样本

  • 所有完成基线12项患者报告结局版常见不良事件术语标准问卷、并接受36.25 Gy/5次SMART的患者,随后在设定时间点用同一分级问卷随访。
  • 共69例患者,中位随访27个月,队列中位年龄73岁(范围54-85岁)。

主要发现

  • 随访期间无患者出现生化失败。
  • 肠道症状方面,随访期间超过80%男性报告无基线毒性变化,新发≥频繁或几乎持续腹泻见于9%患者,「几乎持续」腹泻在1个月达峰但33个月以上时不存在。
  • 泌尿症状方面,尿急加重最常见(39%),20%男性报告新发≥频繁或几乎持续尿急,1个月达峰但33个月以上时不存在。
  • 新发「严重」性功能障碍见于26%患者,且在33个月以上持续存在。

关键数值与推荐

  • 放疗方案为36.25 Gy分5次。
  • 基线中位前列腺特异性抗原为7.5 mmol/L(范围4.5-32 mmol/L),中位T分期为T2b(范围T2-T3b),中位Gleason评分为7(3+4;范围6-9)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report acute and late bowel, urinary, and sexual dysfunction patient-reported outcome measures, among patients with localized prostate cancer who underwent stereotactic magnetic resonance-guided daily adaptive radiation therapy (SMART). METHODS AND MATERIALS: All patients who completed a baseline 12-item Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events questionnaire, before undergoing SMART with 36.25 Gy in 5 fractions, were subsequently followed up with the same graded questionnaire at set time points. Latest prostate-specific antigen levels were recorded. The percentage of patients who reported no change from their baseline adverse event (AE) or reported a new ≥ "frequent or almost constant" or "severe grade or higher" AE grade during follow-up was calculated. The maximum 12-item Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events grade for each item was recorded for each patient. The percentage of toxicity levels for each separate AE item at set time points was calculated. RESULTS: The total number of patients was 69 with a median follow-up of 27 months. Median age of the cohort was 73 years (range, 54-85 years). The median pretreatment prostate-specific antigen level, T stage, and Gleason score were 7.5 mmol/L (range, 4.5-32 mmol/L), T2b (range, T2-T3b), and 7 (3 + 4; range, 6-9), respectively. No patient had biochemical failure during follow-up. Regarding bowel symptoms, >80% of men reported no change from baseline toxicity during follow-up. New ≥ frequent or almost constant diarrhea was reported in 9% of patients. "Almost constant" diarrhea peaked at 1 month but was absent at >33 months. Regarding urinary symptoms, increased urinary urgency was the most common complaint (39%). Twenty percent of men reported new ≥ frequent or almost constant urinary urgency incidence peaking at 1 month but absent at >33 months. New "severe" sexual dysfunction was seen in 26% of patients and was persistent at >33 months. CONCLUSIONS: Our study is one the largest patient-reported outcomes study after prostate SMART. It shows acceptable levels of toxicity even up to 2 years after treatment.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Nugent K, Das P, Ford D, et al. Stereotactic Magnetic Resonance-Guided Daily Adaptive Radiation Therapy for Localized Prostate Cancer: Acute and Late Patient-Reported Toxicity Outcomes. Adv Radiat Oncol. 2024. PMID: 39224488. doi:10.1016/j.adro.2024.101574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。